ReviewFrontiers in immunology2026
Circulating tumor DNA in lung cancer immunotherapy: prognostic marker today, predictive tool tomorrow?
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating tumor DNA (ctDNA) is emerging as a minimally invasive biomarker for risk stratification and treatment-response assessment in lung cancer immunotherapy, but its routine use for treatment selection has not been established. This review critically evaluates evidence across neoadjuvant, adjuvant, consolidation after definitive chemoradiotherapy, and advanced/metastatic settings, with emphasis on serial sampling and on the distinction among prognostic, response-associated, and predictive roles. Across disease stages, baseline or post-definitive-treatment ctDNA detectability consistently identifies patients at increased risk of recurrence or death and is therefore principally prognostic. Early on-treatment decline or clearance frequently precedes radiographic change and is associated with pathological response, progression-free survival, and overall survival, supporting ctDNA as a response-associated biomarker. By contrast, evidence that ctDNA identifies differential benefit from a specific immunotherapy remains limited, because most analyses are single-arm and/or retrospective, formal treatment-by-biomarker interaction tests are uncommon, and prospective ctDNA-guided trials have not yet demonstrated clinical utility. Nevertheless, ctDNA dynamics provide a biologically and clinically coherent framework for future risk-adapted strategies, including enrichment of molecular residual disease-positive patients, early identification of resistance, and prospective testing of treatment escalation, de-escalation, or duration. Translation into routine care will require harmonized assays and sampling time points, improved sensitivity at low disease burden, control of clonal hematopoiesis, and randomized interventional validation. Thus, ctDNA currently functions mainly as a prognostic and response-associated biomarker in lung cancer immunotherapy, while its predictive, decision-defining role remains an important but investigational objective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.